In comparison to sulfonylureas, GLP-1 agonists and SGLT-2 inhibitors were linked to favorable outcomes, such as decreased HbA1c, weight, blood pressure, and a lower incidence of hypoglycemia, highlighting GLP-1's ability to lower the occurrence of hypoglycemia when fasting during the holy month of Ramadan [27]. The gene discussed is GLP1R; the disease is Hypoglycemia.